{
  "url": "https://allermi-site.vercel.app/allermi/allermi-vs-astepro/",
  "collection": "allermi",
  "slug": "allermi-vs-astepro",
  "frontmatter": {
    "title": "Allermi vs Astepro: Compounded Multi-Ingredient vs OTC Antihistamine",
    "description": "Single-active OTC vs four-active compounded Rx: decision matrix for allergic rhinitis escalation.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "allermi vs astepro",
    "ymylTier": "medium",
    "citations": [],
    "tldr": "Astepro is OTC azelastine alone, fast relief of sneezing/itching/runny nose in 15 minutes. Allermi compounds up to four ingredients including azelastine plus a steroid and optional anticholinergic and micro-dose decongestant. If Astepro alone is enough, no medical reason to escalate. If congestion isn't covered or symptoms persist, Allermi provides the multi-mechanism escalation.",
    "claims": [
      "c-001",
      "c-007",
      "c-009",
      "c-010",
      "c-011",
      "c-035",
      "c-036",
      "c-048"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Astepro = one OTC active; Allermi = up to 4 compounded Rx actives",
        "tier": "fda-label"
      },
      {
        "text": "Astepro works in 15 min; Allermi combines fast + long-term control",
        "tier": "fda-label"
      },
      {
        "text": "Allermi not prescribed in pregnancy/breastfeeding or under 18",
        "tier": "expert"
      }
    ],
    "related": [
      {
        "href": "/reviews/astepro/",
        "label": "Astepro review",
        "kind": "Product",
        "description": "Standalone OTC azelastine."
      },
      {
        "href": "/reviews/allermi/",
        "label": "Allermi review",
        "kind": "Product",
        "description": "Compounded 4-active Rx."
      },
      {
        "href": "/reviews/dymista/",
        "label": "Dymista review",
        "kind": "Product",
        "description": "FDA-approved 2-active combo (azelastine + fluticasone)."
      },
      {
        "href": "/allermi/allermi-vs-flonase/",
        "label": "Allermi vs Flonase",
        "kind": "Head-to-head",
        "description": "Compounded combo vs OTC steroid alone."
      },
      {
        "href": "/allermi/allermi-vs-dymista/",
        "label": "Allermi vs Dymista",
        "kind": "Head-to-head",
        "description": "Compounded 4-active vs FDA-approved 2-active."
      },
      {
        "href": "/compare/flonase-vs-astepro/",
        "label": "Flonase vs Astepro",
        "kind": "Head-to-head",
        "description": "OTC stacking rationale."
      },
      {
        "href": "/symptom/itchy-nose/",
        "label": "Best nasal spray for itchy nose",
        "kind": "Symptom",
        "description": "Where azelastine's 15-min onset shines."
      },
      {
        "href": "/symptom/runny-nose/",
        "label": "Best nasal spray for runny nose",
        "kind": "Symptom",
        "description": "Azelastine + ipratropium combos for runny nose."
      }
    ],
    "competitor": {
      "id": "astepro",
      "name": "Astepro"
    }
  },
  "outline": [],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 4,
    "guideline": 0,
    "fdaLabel": 2,
    "cohort": 0,
    "expert": 2
  },
  "claimIds": [
    "c-001",
    "c-007",
    "c-009",
    "c-010",
    "c-011",
    "c-035",
    "c-036",
    "c-048"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n<aside class=\"material-connection-disclosure\" role=\"note\" aria-label=\"Material connection disclosure\">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>\n\n<Claim id=\"c-035\">In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray</Claim> <Claim id=\"c-036\">In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)</Claim> <Claim id=\"c-001\">Azelastine is a fast-acting intranasal H1-receptor antihistamine that blocks histamine — a chemical released during allergic reactions — to relieve sneezing, itchy nose, runny nose, and nasal congestion</Claim> <Claim id=\"c-007\">In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment</Claim> <Claim id=\"c-048\">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id=\"c-009\">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim> <Claim id=\"c-010\">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim> <Claim id=\"c-011\">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim>\n\n<CitationList items={[\n { id: \"1\", title: \"Seidman 2015: Combined therapy systematic review\", url: \"https://pubmed.ncbi.nlm.nih.gov/25644617/\", publisher: \"PubMed\" }\n]} />",
  "claims": [
    {
      "id": "c-001",
      "claim": "Azelastine is a fast-acting intranasal H1-receptor antihistamine that blocks histamine — a chemical released during allergic reactions — to relieve sneezing, itchy nose, runny nose, and nasal congestion",
      "allermi_claim_id": "A1",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "allermi",
        "astepro",
        "dymista"
      ],
      "ymyl_tier": "medium",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/17723160/"
    },
    {
      "id": "c-007",
      "claim": "In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment",
      "allermi_claim_id": "A7",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista",
        "allermi"
      ],
      "ymyl_tier": "medium",
      "qualifiers_required": [
        "suggests",
        "can provide",
        "for many patients"
      ]
    },
    {
      "id": "c-009",
      "claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
      "allermi_claim_id": "C2",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-010",
      "claim": "Allermi is currently available to eligible patients ages 13 and older across most US states",
      "allermi_claim_id": "C1",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-011",
      "claim": "Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections",
      "allermi_claim_id": "B3",
      "source_url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
      "source_type": "FDA",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team (legal-reviewed)"
    },
    {
      "id": "c-035",
      "claim": "In June 2021, the FDA approved Astepro Allergy (azelastine HCl 205.5 mcg per spray) as the first over-the-counter antihistamine nasal spray",
      "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213872Orig1s000Lbl.pdf",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "astepro"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-036",
      "claim": "In a placebo-controlled trial of azelastine nasal spray 0.15%, onset of symptom relief was reported within 30 minutes of dosing (Shah 2009)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/19930788/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "astepro",
        "dymista",
        "allermi"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-048",
      "claim": "Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista",
        "flonase",
        "astepro",
        "allermi"
      ],
      "ymyl_tier": "medium"
    }
  ]
}